Resveratrol Supplementation Reduces Aortic Atherosclerosis and Calcification and Attenuates Loss of Aerobic Capacity in a Mouse Model of Uremia

Journal of Medicinal Food

Volumn 17, Issue 2, 2014, Pages 278-283

  Tomayko, Emily J ^a   Cachia, Andrea J ^a   Chung, Hae R ^a   Wilund, Kenneth R ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

atherosclerosis; bone; calcification; exercise; resveratrol; uremia

Indexed keywords

ANIMALS; AORTA; CALCINOSIS; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; OXYGEN; STILBENES; UREMIA;

EID: 84894421075     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.0219     Document Type: Article

References (28)

1. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493-506.
2. Wenzel E, Somoza V: Metabolism and bioavailability of transresveratrol. Mol Nutr Food Res 2005;49:472-481.
3. Dai Z, Li Y, Quarles LD, et al.: Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 2007;14:806-814.
4. Liu ZP, Li WX, Yu B, et al.: Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J Med Food 2005;8:14-19.
5. Lagouge M, Argmann C, Gerhart-Hines Z, et al.: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127: 1109-1122.
6. Coresh J, Selvin E, Stevens LA, et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
7. Painter P, Carlson L, Carey S, Paul SM, Myll J: Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis 2000;35:482-492.
8. Goodman WG, London G, Amann K, et al.: Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004;43:572-579.
9. Stehman-Breen CO, Sherrard DJ, Alem AM, et al.: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:2200-2205.
10. BuzelloM, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K: The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003;14:311-316.
11. Phan O, Ivanovski O, Nguyen-Khoa T, et al.: Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005;112:2875-2882.
12. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al.: The antioxidant N-Acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005;67: 2288-2294.
13. Daugherty A, Whitman SC: Quantification of atherosclerosis in mice. Methods Mol Biol 2003;209:293-309.
14. Liuba P, Karnani P, Pesonen E, et al.: Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 2000;102:1039-1044.
15. Liuba P, Pesonen E, Paakkari I, et al.: Co-infection with Chlamydia pneumoniae and Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1 expression in apoE-knockout mice. J Vasc Res 2003;40:115-122.
16. Tomayko EJ, Chung HR, Wilund KR: Soy protein diet and exercise training increase relative bone volume and enhance bone micro architecture in a mouse model of uremia. J Bone Miner Metab 2011;29:682-690.
17. Weaver CM, Janle E, Martin B, et al.: Dairy versus calcium carbonate in promoting peak bone mass and bone maintenance during subsequent calcium deficiency. J Bone Miner Res 2009;24:1411-1419.
18. Fukao H, Ijiri Y, Miura M, et al.: Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis 2004;15:441-446.
19. Auger C, Teissedre PL, Gerain P, et al.: Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect hypercholesterolemic hamsters against aortic fatty streak accumulation. J Agric Food Chem 2005;53:2015-2021.
20. Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM: Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med 2005;16:533-540.
21. Zang M, Xu S, Maitland-Toolan KA, et al.: Polyphenols stimulate AMP-Activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006;55:2180-2191.
22. Norata GD, Marchesi P, Passamonti S, Pirillo A, Violi F, Catapano AL: Anti-inflammatory and anti-Atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 2007;191:265-271.
23. Olas B, Wachowicz B: Resveratrol and vitamin C as antioxidants in blood platelets. Thromb Res 2002;106:143-148.
24. Zbikowska HM, Olas B, Wachowicz B, Krajewski T: Response of blood platelets to resveratrol. Platelets 1999;10: 247-252.
25. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT: Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999;6:79-84.
26. Barreto FC, Barreto DV, Liabeuf S, Drueke TB, Massy ZA: Effects of uremic toxins on vascular and bone remodeling. Semin Dial 2009;22:433-437.
27. Lin J, Wu H, Tarr PT, et al.: Transcriptional co-Activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002;418:797-801.
28. Baur JA, Pearson KJ, Price NL, et al.: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342.